期刊
TRANSPLANT INFECTIOUS DISEASE
卷 24, 期 6, 页码 -出版社
WILEY
DOI: 10.1111/tid.13977
关键词
cellular therapy; cytomegalovirus immunoglobulin (CMVIG); hematopoietic stem cell transplant; prophylaxis; solid organ transplant; treatment; vaccine
资金
- Biotest AG
This review provides an overview of the presentations given at the CMV Symposium in September 2021, focusing on CMV infection after solid organ or hematopoietic stem cell transplantation. The topics discussed include CMV epidemiology and diagnosis, the burden of CMV infection and disease, CMV-specific immunity, and management of CMV in transplant settings. Major advances in prevention and treatment of CMV, as well as increased understanding of CMV immunity, have led to improved patient outcomes. Future management algorithms may be personalized based on the immune profile of transplant recipients, marking a new era for CMV patients.
The CMV Symposium in September 2021 was an international conference dedicated to cytomegalovirus (CMV) infection after solid organ or hematopoietic stem cell transplantation. This review provides an overview of the presentations given by the expert faculty, supplemented with educational clinical cases. Topics discussed include CMV epidemiology and diagnosis, the burden of CMV infection and disease, CMV-specific immunity and management of CMV in transplant settings. Major advances in the prevention and treatment of CMV in the past decade and increased understanding of CMV immunity have led to improved patient outcomes. In the future, management algorithms may be individualized based on the transplant recipient's immune profile, which will mark the start of a new era for patients with CMV.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据